Ocugen Inc. (NASDAQ:OCGN) shares traded -0.08% lower at $0.60 on Wall Street last session.
In accordance with the data, 6 analysts cover Ocugen Inc. (NASDAQ:OCGN). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $8.00 and a low of $2.50, we find $4.50. Given the previous closing price of $0.60, this indicates a potential upside of 650.0 percent. OCGN stock price is now 6.15% away from the 50-day moving average and -43.99% away from the 200-day moving average. The market capitalization of the company currently stands at $158.73M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
It has been rated a hold by 0 analysts and a buy by 6. Brokers who have rated the stock have averaged $4.58 as their price target over the next twelve months.
With the price target maintained at $3.50, Chardan Capital Markets recently Upgraded its rating from Neutral to Buy for Ocugen Inc. (NASDAQ: OCGN).
In other news, Zhang Junge, Director bought 200,278 shares of the company’s stock on Jun 14. The stock was bought for $99,999 at an average price of $0.50. Upon completion of the transaction, the Director now directly owns 1,077,182 shares in the company, valued at $0.65 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 16, Chief Executive Officer Musunuri Shankar sold 100,000 shares of the business’s stock. A total of $108,000 was realized by selling the stock at an average price of $1.08. This leaves the insider owning 2,190,073 shares of the company worth $1.31 million. A total of 0.40% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in OCGN stock. A new stake in Ocugen Inc. shares was purchased by ERGOTELES LLC during the first quarter worth $910,000. MILLENNIUM MANAGEMENT LLC invested $761,000 in shares of OCGN during the first quarter. In the first quarter, HRT FINANCIAL LP acquired a new stake in Ocugen Inc. valued at approximately $605,000. CENTIVA CAPITAL, LP acquired a new stake in OCGN for approximately $143,000. Y-INTERCEPT (HONG KONG) LTD purchased a new stake in OCGN valued at around $133,000 in the second quarter. In total, there are 161 active investors with 37.90% ownership of the company’s stock.
Ocugen Inc. (NASDAQ: OCGN) opened at $0.6050 on Thursday. During the past 12 months, Ocugen Inc. has had a low of $0.44 and a high of $2.95. As of last week, the company has a debt-to-equity ratio of 0.03, a current ratio of 5.40, and a quick ratio of 5.40. The fifty day moving average price for OCGN is $0.5629 and a two-hundred day moving average price translates $1.0654 for the stock.
The latest earnings results from Ocugen Inc. (NASDAQ: OCGN) was released for Mar, 2023.
Ocugen Inc.(OCGN) Company Profile
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. It has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
